SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-018819
Filing Date
2022-09-23
Accepted
2022-09-23 16:05:30
Documents
12
Period of Report
2022-09-19
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20220919.htm   iXBRL 8-K 63129
  Complete submission text file 0000950170-22-018819.txt   183626

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20220919_lab.xml EX-101.LAB 13916
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20220919.xsd EX-101.SCH 2463
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20220919_pre.xml EX-101.PRE 10229
6 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20220919_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 221262370
SIC: 2834 Pharmaceutical Preparations